FILE:JPM/JPM-8K-20080730171914.txt.gz
EVENTS:	Financial Statements and Exhibits
TEXT:
ITEM: Financial Statements and Exhibits
 
 
 
 
 
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
o
 
 
 
 
 
The following Exhibits are incorporated by reference into the Registration Statement on Form S-3ASR (333-130051) of JPMorgan Chase & Co. (the Registrant) as exhibits thereto and are filed as part of this Current Report.
 
 
2
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
Dated: July 30, 2008
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3
 
 
 
 
4

 
Exhibit 8.1
JPMorgan Chase & Co.
270 Park Avenue
New York, New York 10017
 
Ladies and Gentlemen:
We have acted as special tax counsel to JPMorgan Chase & Co., a corporation incorporated under the laws of Delaware (the Company), in connection with the preparation and filing of pricing supplement no. 1454 dated July 28, 2008 relating to $12,067,210 Notes linked to a Multi-Asset Portfolio due July 31, 2013 (the Pricing Supplement) to product supplement no. UBS-1 dated July 3, 2008 relating to 100% Principal Protection Notes Linked to a Multi-Asset Portfolio (the Product Supplement) to a prospectus supplement dated October 12, 2006 (the Prospectus Supplement) for the Companys Global Medium-Term Notes, Series E, Global Warrants, Series E and Global Units, Series E, relating to a prospectus dated December 1, 2005 (the Prospectus) contained in the Companys Registration Statement on Form S-3ASR (Registration Statement No. 333-130051) (the Registration Statement).  This opinion is being furnished in accordance with the requirements of Section 601(b)(8) of Regulation S-K of the Securities Act of 1933, as amended (the Act).
In our opinion, the discussions under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading What Are the Tax Consequences of the Notes?  Taxed as Contingent Payment Debt Instruments in the Pricing Supplement, subject to the conditions and limitations described therein, set forth the material U.S. federal income tax considerations applicable generally to holders of the securities offered pursuant to the Pricing Supplement as a result of the ownership and disposition of such securities.
We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the references to us under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading What Are the Tax Consequences of the Notes?  Taxed as Contingent Payment Debt Instruments in the Pricing Supplement.  By such consent we do not concede that we are an expert for the purposes of the Act.

 
Exhibit 8.2
JPMorgan Chase & Co.
270 Park Avenue
New York, New York 10017
 
Ladies and Gentlemen:
We have acted as special tax counsel to JPMorgan Chase & Co., a corporation incorporated under the laws of Delaware (the Company), in connection with the preparation and filing of pricing supplement no. 1456 dated July 28, 2008 relating to $2,430,000 Principal Protected Notes Linked to an Equally Weighted Basket Consisting of the S&P 500 Index, the Dow Jones EURO STOXX 50 Index, and the FTSE/Xinhua China 25 Index due August 2, 2012 (the Pricing Supplement) to product supplement no. 32-X dated April 18, 2008 relating to Principal Protected Notes Linked to a Weighted Basket Consisting of the AMEX Hong Kong 30 Index, the Dow Jones EURO STOXX 50 Index, the Dow Jones  AIG Commodity IndexSM, the S&P GSCI Excess Return Index, the S&P GSCI Agriculture Index Excess Return, the S&P GSCI Energy Index Excess Return, the S&P GSCI Industrial Metals Index Excess Return, the S&P GSCI Livestock Index Excess Return, the S&P GSCI Precious Metals Index Excess Return, the FTSETM 100 Index, the FTSE/Xinhua China 25 Index, the Korea Stock Price Index 200, the MSCI EAFE Index, the iShares MSCI Emerging Markets Index Fund, the MSCI Taiwan Index, the MSCI Singapore Index, the Nikkei 225 Index, the Russell 2000 Index, the Russell 3000 Index and the S&P 500 Index, or Linked to Any One of the Foregoing (the Product Supplement) to a prospectus supplement dated October 12, 2006 (the Prospectus Supplement) for the Companys Global Medium-Term Notes, Series E, Global Warrants, Series E and Global Units, Series E, relating to a prospectus dated December 1, 2005 (the Prospectus) contained in the Companys Registration Statement on Form S-3ASR (Registration Statement No. 333-130051) (the Registration Statement).  This opinion is being furnished in accordance with the requirements of Section 601(b)(8) of Regulation S-K of the Securities Act of 1933, as amended (the Act).
In our opinion, the discussions under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Taxed as Contingent Payment Debt Instruments in the Pricing Supplement, subject to the conditions and limitations described therein, set forth the material U.S. federal income tax considerations applicable generally to holders of the securities offered pursuant to the Pricing Supplement as a result of the ownership and disposition of such securities.
We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the references to us under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Taxed as Contingent Payment Debt Instruments in the Pricing Supplement.  By such consent we do not concede that we are an expert for the purposes of the Act.

 
Exhibit 8.3
JPMorgan Chase & Co.
270 Park Avenue
New York, New York 10017
 
Ladies and Gentlemen:
We have acted as special tax counsel to JPMorgan Chase & Co., a corporation incorporated under the laws of Delaware (the Company), in connection with the preparation and filing of pricing supplement no. 1457 dated July 28, 2008 relating to $13,474,000 Buffered Return Enhanced Notes Linked to the S&P 500 Index due January 29, 2010 (the Pricing Supplement) to product supplement no. 39-XI dated June 11, 2008 relating to Return Enhanced Notes Linked to a Weighted Basket Consisting of One or More of the S&P 500 Index, the S&P MidCap 400 Index, the S&P BRIC 40 Index, the Nikkei 225 Index, the Dow Jones EURO STOXX 50 Index, the Dow Jones U.S. Real Estate Index, the Dow Jones  AIG Commodity IndexSM, the FTSE 100 Index, the MSCI EAFE Index, the MSCI World IndexSM, the NASDAQ-100 Index, the Russell 1000 Growth Index, the Russell 1000 Value Index, the Russell 2000 Index, the iShares Dow Jones U.S. Real Estate Index Fund, the iShares MSCI Emerging Markets Index Fund, the SPDR S&P Homebuilders ETF, the Financial Select Sector SPDR Fund and the Vanguard Emerging Markets ETF (the Product Supplement) to a prospectus supplement dated October 12, 2006 (the Prospectus Supplement) for the Companys Global Medium-Term Notes, Series E, Global Warrants, Series E and Global Units, Series E, relating to a prospectus dated December 1, 2005 (the Prospectus) contained in the Companys Registration Statement on Form S-3ASR (Registration Statement No. 333-130051) (the Registration Statement).  This opinion is being furnished in accordance with the requirements of Section 601(b)(8) of Regulation S-K of the Securities Act of 1933, as amended (the Act).
In our opinion, the discussions under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Capital Gains Tax Treatment in the Pricing Supplement, subject to the conditions and limitations described therein, set forth the material U.S. federal income tax considerations applicable generally to holders of the securities offered pursuant to the Pricing Supplement as a result of the ownership and disposition of such securities.
We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the references to us under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Capital Gains Tax Treatment in the Pricing Supplement.  By such consent we do not concede that we are an expert for the purposes of the Act.

 
Exhibit 8.4
JPMorgan Chase & Co.
270 Park Avenue
New York, New York 10017
 
Ladies and Gentlemen:
We have acted as special tax counsel to JPMorgan Chase & Co., a corporation incorporated under the laws of Delaware (the Company), in connection with the preparation and filing of pricing supplement no. 1458 dated July 28, 2008 relating to $1,382,000 Buffered Return Enhanced Notes Linked to the S&P 500 Index due January 29, 2010 (the Pricing Supplement) to product supplement no. 39-XI dated June 11, 2008 relating to Return Enhanced Notes Linked to a Weighted Basket Consisting of One or More of the S&P 500 Index, the S&P MidCap 400 Index, the S&P BRIC 40 Index, the Nikkei 225 Index, the Dow Jones EURO STOXX 50 Index, the Dow Jones U.S. Real Estate Index, the Dow Jones  AIG Commodity IndexSM, the FTSE 100 Index, the MSCI EAFE Index, the MSCI World IndexSM, the NASDAQ-100 Index, the Russell 1000 Growth Index, the Russell 1000 Value Index, the Russell 2000 Index, the iShares Dow Jones U.S. Real Estate Index Fund, the iShares MSCI Emerging Markets Index Fund, the SPDR S&P Homebuilders ETF, the Financial Select Sector SPDR Fund and the Vanguard Emerging Markets ETF (the Product Supplement) to a prospectus supplement dated October 12, 2006 (the Prospectus Supplement) for the Companys Global Medium-Term Notes, Series E, Global Warrants, Series E and Global Units, Series E, relating to a prospectus dated December 1, 2005 (the Prospectus) contained in the Companys Registration Statement on Form S-3ASR (Registration Statement No. 333-130051) (the Registration Statement).  This opinion is being furnished in accordance with the requirements of Section 601(b)(8) of Regulation S-K of the Securities Act of 1933, as amended (the Act).
In our opinion, the discussions under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Capital Gains Tax Treatment in the Pricing Supplement, subject to the conditions and limitations described therein, set forth the material U.S. federal income tax considerations applicable generally to holders of the securities offered pursuant to the Pricing Supplement as a result of the ownership and disposition of such securities.
We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the references to us under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Capital Gains Tax Treatment in the Pricing Supplement.  By such consent we do not concede that we are an expert for the purposes of the Act.

 
Exhibit 8.5
JPMorgan Chase & Co.
270 Park Avenue
New York, New York 10017
 
Ladies and Gentlemen:
We have acted as special tax counsel to JPMorgan Chase & Co., a corporation incorporated under the laws of Delaware (the Company), in connection with the preparation and filing of pricing supplement no. 1459 dated July 28, 2008 relating to $5,052,000 Buffered Return Enhanced Notes Linked to the MSCI EAFE Index due January 29, 2010 (the Pricing Supplement) to product supplement no. 39-XI dated June 11, 2008 relating to Return Enhanced Notes Linked to a Weighted Basket Consisting of One or More of the S&P 500 Index, the S&P MidCap 400 Index, the S&P BRIC 40 Index, the Nikkei 225 Index, the Dow Jones EURO STOXX 50 Index, the Dow Jones U.S. Real Estate Index, the Dow Jones  AIG Commodity IndexSM, the FTSE 100 Index, the MSCI EAFE Index, the MSCI World IndexSM, the NASDAQ-100 Index, the Russell 1000 Growth Index, the Russell 1000 Value Index, the Russell 2000 Index, the iShares Dow Jones U.S. Real Estate Index Fund, the iShares MSCI Emerging Markets Index Fund, the SPDR S&P Homebuilders ETF, the Financial Select Sector SPDR Fund and the Vanguard Emerging Markets ETF (the Product Supplement) to a prospectus supplement dated October 12, 2006 (the Prospectus Supplement) for the Companys Global Medium-Term Notes, Series E, Global Warrants, Series E and Global Units, Series E, relating to a prospectus dated December 1, 2005 (the Prospectus) contained in the Companys Registration Statement on Form S-3ASR (Registration Statement No. 333-130051) (the Registration Statement).  This opinion is being furnished in accordance with the requirements of Section 601(b)(8) of Regulation S-K of the Securities Act of 1933, as amended (the Act).
In our opinion, the discussions under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Capital Gains Tax Treatment in the Pricing Supplement, subject to the conditions and limitations described therein, set forth the material U.S. federal income tax considerations applicable generally to holders of the securities offered pursuant to the Pricing Supplement as a result of the ownership and disposition of such securities.
We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the references to us under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Capital Gains Tax Treatment in the Pricing Supplement.  By such consent we do not concede that we are an expert for the purposes of the Act.

 
Exhibit 8.6
JPMorgan Chase & Co.
270 Park Avenue
New York, New York 10017
 
Ladies and Gentlemen:
We have acted as special tax counsel to JPMorgan Chase & Co., a corporation incorporated under the laws of Delaware (the Company), in connection with the preparation and filing of pricing supplement no. 1460 dated July 28, 2008 relating to $2,901,000 Principal Protected Asset Allocation Notes Linked to the Performance of the Best Performing of the Three Reference Portfolios Each Comprised of Four Asset Classes:  (1) a Weighted Basket of the British Pound, the Euro and the Japanese Yen Relative to the U.S. Dollar, (2) the Dow Jones  AIG Commodities IndexSM, (3) the JPMorgan GBI Global Bond Total Return Index Hedged into U.S. Dollars and (4) a Weighted Basket of the S&P 500 Index, the Dow Jones EURO STOXX 50 Index and the Nikkei 225 Index due July 31, 2013 (the Pricing Supplement) to product supplement no. 109-I dated December 31, 2007 relating to Principal Protected Asset Allocation Notes Linked to the Performance of the Best Performing of the Three Reference Portfolios Each Comprised of Four Asset Classes (the Product Supplement) to a prospectus supplement dated October 12, 2006 (the Prospectus Supplement) for the Companys Global Medium-Term Notes, Series E, Global Warrants, Series E and Global Units, Series E, relating to a prospectus dated December 1, 2005 (the Prospectus) contained in the Companys Registration Statement on Form S-3ASR (Registration Statement No. 333-130051) (the Registration Statement).  This opinion is being furnished in accordance with the requirements of Section 601(b)(8) of Regulation S-K of the Securities Act of 1933, as amended (the Act).
In our opinion, the discussions under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Taxed as Contingent Payment Debt Instruments in the Pricing Supplement, subject to the conditions and limitations described therein, set forth the material U.S. federal income tax considerations applicable generally to holders of the securities offered pursuant to the Pricing Supplement as a result of the ownership and disposition of such securities.
We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the references to us under the heading Selected Purchase Considerations  Taxed as Contingent Payment Debt Instruments in the Pricing Supplement.  By such consent we do not concede that we are an expert for the purposes of the Act.

 
Exhibit 8.7
JPMorgan Chase & Co.
270 Park Avenue
New York, New York 10017
 
Ladies and Gentlemen:
We have acted as special tax counsel to JPMorgan Chase & Co., a corporation incorporated under the laws of Delaware (the Company), in connection with the preparation and filing of pricing supplement no. 1461 dated July 28, 2008 relating to $2,924,000 Principal Protected Asset Allocation Notes Linked to the Performance of the Best Performing of the Three Reference Portfolios Each Comprised of Four Asset Classes:  (1) a Weighted Basket of the British Pound, the Euro and the Japanese Yen Relative to the U.S. Dollar, (2) the Dow Jones  AIG Commodities IndexSM, (3) the JPMorgan GBI Global Bond Total Return Index Hedged into U.S. Dollars and (4) a Weighted Basket of the S&P 500 Index, the Dow Jones EURO STOXX 50 Index and the Nikkei 225 Index due July 31, 2014 (the Pricing Supplement) to product supplement no. 109-I dated December 31, 2007 relating to Principal Protected Asset Allocation Notes Linked to the Performance of the Best Performing of the Three Reference Portfolios Each Comprised of Four Asset Classes (the Product Supplement) to a prospectus supplement dated October 12, 2006 (the Prospectus Supplement) for the Companys Global Medium-Term Notes, Series E, Global Warrants, Series E and Global Units, Series E, relating to a prospectus dated December 1, 2005 (the Prospectus) contained in the Companys Registration Statement on Form S-3ASR (Registration Statement No. 333-130051) (the Registration Statement).  This opinion is being furnished in accordance with the requirements of Section 601(b)(8) of Regulation S-K of the Securities Act of 1933, as amended (the Act).
In our opinion, the discussions under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Taxed as Contingent Payment Debt Instruments in the Pricing Supplement, subject to the conditions and limitations described therein, set forth the material U.S. federal income tax considerations applicable generally to holders of the securities offered pursuant to the Pricing Supplement as a result of the ownership and disposition of such securities.
We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the references to us under the heading Selected Purchase Considerations  Taxed as Contingent Payment Debt Instruments in the Pricing Supplement.  By such consent we do not concede that we are an expert for the purposes of the Act.

 
Exhibit 8.8
JPMorgan Chase & Co.
270 Park Avenue
New York, New York 10017
 
Ladies and Gentlemen:
We have acted as special tax counsel to JPMorgan Chase & Co., a corporation incorporated under the laws of Delaware (the Company), in connection with the preparation and filing of pricing supplement no. 1462 dated July 28, 2008 relating to $9,258,000 Principal Protected Dual Directional Notes Linked to a Weighted Basket Consisting of Three Commodities and Three Commodity Indices due July 31, 2013  (the Pricing Supplement) to product supplement no. 102-I dated October 15, 2007 relating to Principal Protected Dual Directional Notes Linked to a Weighted Basket Consisting of up to Thirteen Commodities and/or Five Commodity Indices, or Linked to Any One of the Foregoing (the Product Supplement) to a prospectus supplement dated October 12, 2006 (the Prospectus Supplement) for the Companys Global Medium-Term Notes, Series E, Global Warrants, Series E and Global Units, Series E, relating to a prospectus dated December 1, 2005 (the Prospectus) contained in the Companys Registration Statement on Form S-3ASR (Registration Statement No. 333-130051) (the Registration Statement).  This opinion is being furnished in accordance with the requirements of Section 601(b)(8) of Regulation S-K of the Securities Act of 1933, as amended (the Act).
In our opinion, the discussions under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Taxed as Contingent Payment Debt Instruments in the Pricing Supplement, subject to the conditions and limitations described therein, set forth the material U.S. federal income tax considerations applicable generally to holders of the securities offered pursuant to the Pricing Supplement as a result of the ownership and disposition of such securities.
We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the references to us under the heading Selected Purchase Considerations  Taxed as Contingent Payment Debt Instruments in the Pricing Supplement.  By such consent we do not concede that we are an expert for the purposes of the Act.

 
Exhibit 8.9
JPMorgan Chase & Co.
270 Park Avenue
New York, New York 10017
 
Ladies and Gentlemen:
We have acted as special tax counsel to JPMorgan Chase & Co., a corporation incorporated under the laws of Delaware (the Company), in connection with the preparation and filing of pricing supplement no. 1463 dated July 28, 2008 relating to $4,298,000 Principal Protected Dual Directional Notes Linked to the Performance of an Equally Weighted Basket of Five Currencies Relative to the U.S. Dollar due January 31, 2011 (the Pricing Supplement) to product supplement no. 135-I dated May 1, 2008 relating to Principal Protected Dual Directional Notes Linked to a Weighted Basket Consisting of up to Thirteen Commodities and/or Five Commodity Indices and/or the Performance of One or More Currencies Relative to a Reference Currency, or Linked to Any One of the Foregoing (the Product Supplement) to a prospectus supplement dated October 12, 2006 (the Prospectus Supplement) for the Companys Global Medium-Term Notes, Series E, Global Warrants, Series E and Global Units, Series E, relating to a prospectus dated December 1, 2005 (the Prospectus) contained in the Companys Registration Statement on Form S-3ASR (Registration Statement No. 333-130051) (the Registration Statement).  This opinion is being furnished in accordance with the requirements of Section 601(b)(8) of Regulation S-K of the Securities Act of 1933, as amended (the Act).
 
In our opinion, the discussions under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Taxed as Contingent Payment Debt Instruments in the Pricing Supplement, subject to the conditions and limitations described therein, set forth the material U.S. federal income tax considerations applicable generally to holders of the securities offered pursuant to the Pricing Supplement as a result of the ownership and disposition of such securities.
We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the references to us under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Taxed as Contingent Payment Debt Instruments in the Pricing Supplement.  By such consent we do not concede that we are an expert for the purposes of the Act.

 
Exhibit 8.10
JPMorgan Chase & Co.
270 Park Avenue
New York, New York 10017
 
Ladies and Gentlemen:
We have acted as special tax counsel to JPMorgan Chase & Co., a corporation incorporated under the laws of Delaware (the Company), in connection with the preparation and filing of pricing supplement no. 1464 dated July 28, 2008 relating to $2,062,000 Principal Protected Dual Directional Notes Linked to the Performance of an Equally Weighted Basket of Five Currencies Relative to the U.S. Dollar due January 31, 2011 (the Pricing Supplement) to product supplement no. 135-I dated May 1, 2008 relating to Principal Protected Dual Directional Notes Linked to a Weighted Basket Consisting of up to Thirteen Commodities and/or Five Commodity Indices and/or the Performance of One or More Currencies Relative to a Reference Currency, or Linked to Any One of the Foregoing (the Product Supplement) to a prospectus supplement dated October 12, 2006 (the Prospectus Supplement) for the Companys Global Medium-Term Notes, Series E, Global Warrants, Series E and Global Units, Series E, relating to a prospectus dated December 1, 2005 (the Prospectus) contained in the Companys Registration Statement on Form S-3ASR (Registration Statement No. 333-130051) (the Registration Statement).  This opinion is being furnished in accordance with the requirements of Section 601(b)(8) of Regulation S-K of the Securities Act of 1933, as amended (the Act).
In our opinion, the discussions under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Taxed as Contingent Payment Debt Instruments in the Pricing Supplement, subject to the conditions and limitations described therein, set forth the material U.S. federal income tax considerations applicable generally to holders of the securities offered pursuant to the Pricing Supplement as a result of the ownership and disposition of such securities.
We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the references to us under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Taxed as Contingent Payment Debt Instruments in the Pricing Supplement.  By such consent we do not concede that we are an expert for the purposes of the Act.

 
Exhibit 8.11
JPMorgan Chase & Co.
270 Park Avenue
New York, New York 10017
 
Ladies and Gentlemen:
We have acted as special tax counsel to JPMorgan Chase & Co., a corporation incorporated under the laws of Delaware (the Company), in connection with the preparation and filing of pricing supplement no. 1465 dated July 28, 2008 relating to $1,195,000 Floating Rate Notes Linked to the Consumer Price Index due July 31, 2013 (the Pricing Supplement) to product supplement no. 3-II dated February 13, 2006 relating to Floating Rate Notes Linked to the Consumer Price Index (the Product Supplement) to a prospectus supplement dated December 1, 2005 (the Prospectus Supplement) for the Companys Global Medium-Term Notes, Series E, Global Warrants, Series E and Global Units, Series E, relating to a prospectus dated December 1, 2005 (the Prospectus) contained in the Companys Registration Statement on Form S-3ASR (Registration Statement No. 333-130051) (the Registration Statement).  This opinion is being furnished in accordance with the requirements of Section 601(b)(8) of Regulation S-K of the Securities Act of 1933, as amended (the Act).
In our opinion, the discussions under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Tax Treatment in the Pricing Supplement, subject to the conditions and limitations described therein, set forth the material U.S. federal income tax considerations applicable generally to holders of the securities offered pursuant to the Pricing Supplement as a result of the ownership and disposition of such securities.
We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the references to us under the heading Selected Purchase Considerations  Tax Treatment in the Pricing Supplement.  By such consent we do not concede that we are an expert for the purposes of the Act.


